A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression of motor symptoms in Parkinson’s disease patients with rapidly progressing forms, using phase II clinical trial data.
Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson’s progression
- Post author:
- Post published:April 19, 2024
- Post category:uncategorized